Amidst the hype of Saudi Arabia’s embrace of innovative therapies and technologies, the concepts of access and affordability can often be forgotten. However, the Saudi government remains the dominant healthcare…
Saudi Arabia’s pharmaceutical sector continues its impressive growth leadership within the region. With a 9.1 percent market growth in 2024 and a projected USD 11.6 billion in sales, the Kingdom…
Home to a score of pioneering biopharma players, Denmark has recognized its life sciences industry as a cornerstone of the economy. After forming a public-private partnership forum in 2021, the…
Mexico has a long history of public healthcare reforms that have fluctuated along with the changing tides of the country’s government. The latest is an ambitious plan for the Institute…
After February’s snap election that brought Friedrich Merz to power, a coalition between his conservative CDU/CSU bloc and the centre-left SPD has outlined an agreement this month that will serve…
As a result of its ageing demographic, China has seen a sharp rise in Alzheimer’s Disease (AD). The country’s AD patients over 60 already total some ten million and as…
Australia will shortly have its latest national election, and we are again seeing pharmaceuticals being front and centre in the campaign. The starter’s gun has been fired for the…
After a globe-trotting career that led him to diverse global affiliates, the long-term Takeda executive Rodrigo Rodriguez is going full circle. Returning to where he began his career at the…
Writing in the April 2025 edition of DIA’s Global Forum magazine, Christopher Morrison and Richard Xie of RA Capital Management L.P., introduce the recently published cost-effectiveness analyses methodology which incorporates…
While on the surface it may look like pharmaceuticals have been spared by Donald Trump’s “Liberation Day” trade policies, drugmakers still lack a clear picture of how they will be…
With the proposed Biotech Act, the European Commission (EC) is aiming to boost the EU biotech industry’s competitivity in the face of major rivals like the US and China. Tackling…
This week’s Asia healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers China’s USD 36.2bn in outbound licensing agreements, Henlius & EssexBio meeting Phase III endpoints, Organon acquiring US…
See our Cookie Privacy Policy Here
